(R)-2-(Toluene-4-sulfonylamino)-butyric acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(Toluene-4-sulfonylamino)-butyric acid
• 英文别名: (2R)-2-[(4-methylphenyl)sulfonylamino]butanoic acid
• 化学式: C₁₁H₁₅NO₄S
• 分子量: 257.31
• InChiKey: OCFPTFVQZWHPPH-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  对甲苯磺酰胺 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ (S,S,S,S)-Me-f-KetalPhos 、 甲烷磺酸 、 氢气 、 三乙胺 作用下， 以 乙醇 、 1,2-二氯乙烷 、 甲苯 为溶剂， 25.0 ℃ 、620.53 kPa 条件下， 反应 52.0h， 生成 (R)-2-(Toluene-4-sulfonylamino)-butyric acid
  参考文献：
  名称：

  Asymmetric Hydrogenation of N-Sulfonylated-α-dehydroamino Acids:  Toward the Synthesis of an Anthrax Lethal Factor Inhibitor

  摘要：

  [GRAPHIC]A novel and highly enantioselective Ru-catalyzed hydrogenation of N-sulfonylated-alpha-dehydroamino acids has been discovered and demonstrated in the synthesis of an anthrax lethal factor inhibitor (LFI). Herein, this methodology is used to prepare N-sulfonylated amino acids in up to 98% ee. This unprecedented hydrogenation uses a chiral Ru catalyst rather than Rh as typical for acylated dehydroamino acids and esters, and this work reports the first asymmetric hydrogenation of a tetrasubstituted dehydroamino acid derivative using a Ru catalyst.

  DOI：

  10.1021/ol050869s

文献信息

• [EN] NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS NMDA SÉLECTIFS DU SITE NR2B
  申请人：UNIV MUENSTER WILHELMS

  公开号：WO2010122134A1

  公开（公告）日：2010-10-28

  The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).

  本发明涉及符合一般式（I）的化合物以及包含符合一般式（I）的化合物的药物组合物。
• [EN] NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DU RÉCEPTEUR NMDA SÉLECTIFS DE NR2B POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES À MÉDIATION IMMUNITAIRE
  申请人：WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER

  公开号：WO2017036880A1

  公开（公告）日：2017-03-09

  The present invention provides novel means and methods for treatment auf immunemediated inflammatory diseases.

  本发明提供了治疗免疫介导性炎症性疾病的新手段和方法。
• NR2B-selective NMDA-receptor antagonists
  申请人：Westfälische Wilhelms-Universität Münster

  公开号：EP2246331A1

  公开（公告）日：2010-11-03

  The present invention relates to NMDA antagonists that target the NR2B subunit according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).

  本发明涉及根据通式（I）靶向 NR2B 亚基的 NMDA 拮抗剂和包含根据通式（I）化合物的药物组合物。
• NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES
  申请人：Westfälische Wilhelms-Universität Münster

  公开号：EP3344257A1

  公开（公告）日：2018-07-11
• Asymmetric Hydrogenation of <i>N</i>-Sulfonylated-α-dehydroamino Acids:  Toward the Synthesis of an Anthrax Lethal Factor Inhibitor
  作者：C. Scott Shultz、Spencer D. Dreher、Norihiro Ikemoto、J. Michael Williams、Edward J. J. Grabowski、Shane W. Krska、Yongkui Sun、Peter G. Dormer、Lisa DiMichele

  DOI：10.1021/ol050869s

  日期：2005.8.1

  [GRAPHIC]A novel and highly enantioselective Ru-catalyzed hydrogenation of N-sulfonylated-alpha-dehydroamino acids has been discovered and demonstrated in the synthesis of an anthrax lethal factor inhibitor (LFI). Herein, this methodology is used to prepare N-sulfonylated amino acids in up to 98% ee. This unprecedented hydrogenation uses a chiral Ru catalyst rather than Rh as typical for acylated dehydroamino acids and esters, and this work reports the first asymmetric hydrogenation of a tetrasubstituted dehydroamino acid derivative using a Ru catalyst.